Using the SW620-shRNA stable cell line and the SW620-scramble control cell line, we determined the combinatory effects of c-Met targeting and conventional chemotherapeutic agents for colon cancer in cells with mutated KRAS. Agents with different anti-cancer mechanisms were selected, including traditionally used agents (5-FU, cisplatin, Taxol, and irinotecan) and a targeted agent (sorafenib). Here, KRAS is linked to cancer.